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A B S T R A C T
Background: Several guidelines have been reported for bone-directed treatment in women with early breast
cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of
studies on additional fracture related risk factors, new treatment options as well as real world studies
demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs).
Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position
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Bisphosphonate
Denosumab
statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated
bone loss (AIBL).
Patients and methods: A systematic literature review identiﬁed recent advances in the management of AIBL.
Results with individual agents were assessed based on trial design, size, follow-up, and safety.
Results: Several fracture related risk factors in patients with EBC were identiﬁed. Although, the FRAX algorithm
includes fracture risk factors (RF) in addition to BMD, it does not seem to adequately address the eﬀects of AIBL.
Several antiresorptive agents can prevent and treat AIBL. However, concerns regarding compliance and long-
term safety remain. Overall, the evidence for fracture prevention is strongest for denosumab 60 mg s.c. every 6
months. Additionally, recent studies as well as an individual patient data meta-analysis of all available
randomized trial data support additional anticancer beneﬁts from adjuvant bisphosphonate treatment in
postmenopausal women with a 34% relative risk reduction in bone metastasis and 17% relative risk decrease in
breast cancer mortality that needs to be taken into account when advising on management of AIBL.
Conclusions: In all patients initiating AI treatment, fracture risk should be assessed and recommendation with
regard to exercise and calcium/vitamin D supplementation given. Bone-directed therapy should be given to all
patients with a T-score<−2.0 or with a T-score of< –1.5 SD with one additional RF, or with ≥2 risk factors
(without BMD) for the duration of AI treatment. Patients with T-score>−1.5 SD and no risk factors should be
managed based on BMD loss during the ﬁrst year and the local guidelines for postmenopausal osteoporosis.
Compliance should be regularly assessed as well as BMD on treatment after 12 - 24 months. Furthermore,
because of the decreased incidence of bone recurrence and breast cancer speciﬁc mortality, adjuvant bispho-
sphonates are recommended for all postmenopausal women at signiﬁcant risk of disease recurrence.
1. Introduction
Breast cancer is the most frequent cancer in women leading to a
signiﬁcant morbidity and mortality [1]. Early diagnosis and improved
treatment regimens have signiﬁcantly increased survival leading to a
greater potential for experiencing long term side eﬀects from cancer
treatments including bone loss and fractures. Skeletal homeostasis is
achieved through coupled and balanced bone resorption and bone
formation. Several local and systemic factors regulate these processes,
including estrogen, a key regulator of bone resorption. Physiologic
decreases in estrogen levels after menopause lead to an increased risk
for osteoporosis (low bone mineral density [BMD]) and fractures, and
this risk can be exacerbated by breast cancer and its therapies [2].
Systemic therapies for breast cancer can additionally interfere with
bone turnover, either through their eﬀects on gonadal steroid hormone
production or by inhibiting peripheral aromatization into estrogen
[2–4]. In addition, some therapies for breast cancer might directly
aﬀect bone formation [5]. Regardless of the underlying mechanism,
patients with breast cancer are at risk for cancer treatment-induced
bone loss (CTIBL).
The majority of breast malignancies are hormone responsive, and
adjuvant endocrine therapy is used routinely to prevent breast cancer
recurrence and death [6,7]. Tamoxifen was the past treatment of choice
for endocrine-responsive postmenopausal breast cancer and was found
to preserve BMD in postmenopausal (but not premenopausal) women
[8], and fracture risks remained similar in postmenopausal tamoxifen
users and non-users [9]. However, aromatase inhibitors (AI) have now
replaced tamoxifen as the treatment of choice for hormone-responsive
breast cancer in most postmenopausal women because of both better
eﬃcacy and fewer serious side eﬀects such as induction of uterine
cancers and thromboembolic events.[6,7,10,11] However, because AIs
prevent peripheral estrogen production, they suppress estrogen levels
beyond that attained from a natural menopause, thereby leading to
accelerated bone loss and an increased fracture risk [12–15].
Besides a reduction in quality of life, increased morbidity and
treatment induced fractures lead to an increase in the health economic
burden. A recent study reported that compared to the general popula-
tion, breast cancer patients had fracture incidence rate ratios of 1.25
(95% CI: 1.23–1.28) and 1.18 (95% CI: 1.14–1.22) for hospitalization
due to any bone fracture and hip fracture, respectively. These ratios
remained signiﬁcantly increased for 10 years. Women taking aromatase
inhibitors were at an increased risk of fracture as compared with
women taking tamoxifen (HR 1.48; 95% CI: 0.98–2.22). Additionally,
breast cancer patients hospitalized for a bone fracture showed a higher
risk of death (HR 1.83; 95% CI: 1.50–2.22) compared with those
without bone fracture [16].
1.1. What is the size of the problem?
AI-associated bone loss (AIBL) leads to a marked increase of bone
resorption, with a 2–4 fold increased bone loss compared to physiologic
postmenopausal BMD loss.[12,15,17–24] As a result, women receiving
adjuvant AI therapy for breast cancer are at increased risk for fractures
[25–28], which leads to increased morbidity and mortality [29].
Randomized controlled trials (RCTs) including an AI for 5 years
suggested an increased absolute fracture risk of around 10% indicating
that one out of ten women will eventually fracture [25–28]. However,
these studies had stringent inclusion and exclusion criteria that may not
reﬂect fracture risk in the unselected population seen in routine clinical
practice. The real-world fracture risk has been investigated in a number
of case-control studies, prescription based analysis as well as single
center studies and even in a recent RCT. In the latter, the fracture
incidence in women with BC on an AI was reported to be around
18–20% after 5 years follow-up indicating that in clinical practice,
about one in ﬁve women will sustain an AI related fracture [30–38].
After termination of AI treatment, bone turnover normalizes, BMD and
fracture risk can partially recover [25–28]. Recently, conﬂicting
evidence on the increased duration of AI treatment for up to 10 years
has been reported [39–42]. For those advocating an increased duration
of AI treatment for up to 10 years, a further increased fracture risk,
adding to the 2–3% per annum has to be taken into account.
1.2. How to assess osteoporosis related fracture risk
In 1993, the ﬁrst operational deﬁnition of osteoporosis was based on
a decreased in BMD eg. a T-score at the femur neck of<−2.5 [43,44].
In the past years, we have accumulated an expanded understanding of
fracture risk factors other than BMD [5,45], resulting in several
national and international bone health guidelines being updated to
provide more comprehensive insights into fracture risk assessment and
clinical decision making regarding antiresorptive therapy (Table 1)
[5,6,11,46–53] A key advance in this ﬁeld has been the development of
the FRAX algorithm developed by the former WHO Collaborating
Center at Sheﬃeld, UK (http://www.sheﬃeld.ac.uk/FRAX/), an easy-
to-use online tool for assessing fracture risk in postmenopausal women
with or without BMD data. The FRAX algorithm is based on data from
large-scale, population-based cohorts from diﬀerent parts of the world,
and uses factors such as age, body mass index (BMI), smoking history,
P. Hadji et al. Journal of Bone Oncology 7 (2017) 1–12
2
personal and family history of fracture, smoking, glucocorticoid use,
and secondary causes of osteoporosis, to assess long-term fracture risk.
However, FRAX is not designed to assess fracture risk in women with
breast cancer, and indeed may substantially underestimate the eﬀect of
AI therapy—the “secondary osteoporosis” option in the FRAX tool has a
much smaller eﬀect on fracture risk than would be expected for AI
therapy. Moreover, as clinical trials comparing AIs with tamoxifen
mature, it is evident that AIs have a large eﬀect on acute fracture risk
during active treatment [26,27], which might be underestimated by
FRAX, an algorithm designed to provide long-term (10-year) fracture
risk. As it appears that the independent fracture risk in AIBL is
equivalent to that seen in RA, it has recently been suggested to use
the bypass of rheumatoid arthritis in FRAX as it has been proposed in
type 2 diabetes [54].
With regard to AIBL, a retrospective, case-controlled study in 402
postmenopausal women with newly diagnosed breast cancer demon-
strated that using a combination of BMD and clinical risk factors
identiﬁed more than 28% of these women as candidates for bone-
directed therapy, compared with less than 10% identiﬁed by BMD
criteria alone [55]. Additionally, Neuner et al. [56] reported that age
and BMI were particularly associated with an increased hip fracture risk
in women with breast cancer.
1.3. Additional anticancer beneﬁts of adjuvant bisphosphonates
In past years, a large number of clinical trials investigating the use
of antiresorptive agents, such as bisphosphonates and denosumab (a
monoclonal antibody against the receptor activator of nuclear factor
kappa B ligand [RANKL]), for the prevention and/or treatment of AIBL
have been reported.
Population-based case-control studies suggest that oral bisphospho-
nate treatment for postmenopausal osteoporosis may reduce the
incidence of invasive breast cancers [57–59]. Moreover, phase II studies
have demonstrated direct anticancer eﬀects of zoledronate on dissemi-
nated tumor cells in the bone marrow of patients with early breast
cancer [60–63], and subset analyses from ongoing trials show that the
addition of zoledronate to neo-adjuvant chemotherapy can reduce
residual tumor size and improve pathologic response rates compared
with chemotherapy alone [64].
Early trials of adjuvant bisphosphonates for the prevention of bone
metastases in early breast cancer were promising but inconclusive
[65–68] This was due to the broad inclusion criteria for many of the
trials; it is now clear that adjuvant bisphosphonates have no eﬀects on
breast cancer recurrence or mortality in premenopausal women with all
the beneﬁts restricted to women who are either postmenopausal or
have had a menopause induced postoperatively with goserelin [69,70],
Recently, Coleman et al. conﬁrmed the anticancer eﬀect of bispho-
sphonates in a meta-analysis conducted by the Early Breast Cancer
Clinical Trials Group (EBCTCG), decreasing the incidence of bone
recurrence by 34% and breast cancer speciﬁc mortality by 17% [71].
Additionally, an expert panel of oncologists and bone experts has
published a consensus statement for the use of adjuvant bisphospho-
Table 1
Summary of guidelines for antiresorptive use in women with breast cancera,b.
Source Whom to treat Antiresorptive Dose Duration of
treatment
ESMO [5] All women receiving AI therapy with ≥1 of the following T-score ≤
–2.0. Any 2 of the following risk factors T-score< –1.5, age> 65 yr,
low BMI (< 20 kg/m2), family history of hip fracture, personal history
of fragility fracture after age 50, oral corticosteroid use> 6 mo, and
smoking
Zoledronate 4 mg IV q6mo As long as AI
therapyDenosumab
60 mg SC q6mo As long as AI
therapy
SIOG [5]
ASCO [48] Women with T-score ≤ –2.5 Alendronate Not given Not given
Women with T-score between –1.0 and –2.5 should receive
individualized therapy
Risedronate
Zoledronate
St. Gallen [6] No treatment for women with normal BMD — — —
UK Expert Group [49] Premenopausal women with ovarian suppression/failure and ≥1 of
the following
Alendronate 70 mg/wk Follow-up at 2 yr to
reassessRisedronate 35 mg/wk
AI therapy and T-score< –1.0 Ibandronate 150 mg PO/mo or
3 mg IV q 3 moT-score< –2.0 Zoledronate
Vertebral fracture
Annual bone loss> 4% at LS or TH 4 mg IV q6mo
Postmenopausal women receiving AI therapy with≥1 of the following Alendronate 70 mg/wk Follow-up at 2 yr to
reassessT-score< –2.0 Risedronate 35 mg/wk
Vertebral fracture Ibandronate 150 mg PO/mo or
3 mg IV q 3 moAnnual bone loss> 4% at LS or TH Zoledronate
4 mg IV q6mo
Belgian Bone Club [47] Women with T-score< –2.5 or history of fragility fracture Zoledronate Other BPs may
be considered
4 mg IV q6mo As long as AI
therapyWomen with T-score between –1.0 and –2.5 plus other risk factors
International Expert Group
(Hadji et al.) [5]
All women receiving AI therapy with ≥1 of the following T-score ≤
–2.0. Any 2 of the following risk factors T-score< –1.5, age> 65 yr,
low BMI (< 20 kg/m2), family history of hip fracture, personal history
of fragility fracture after age 50, oral corticosteroid use> 6 mo, and
smoking
Zoledronate 4 mg IV q6mo At least 2 yr,
possibly as long as
AI therapy
International Expert Panel
(Aapro et al.) [46]
Women with ≥2 of the following risk factors: AI use, T-score< –1.5,
age> 65 yr, corticosteroid use> 6 mo, family history of hip fracture,
personal history of fragility fracture after age 50; T-score< –2.0
Zoledronate 4 mg IV q6mo As long as AI
therapy
ESCEO position paper All women receiving AI therapy with (T-score hip/spine<−2.5 or
≥1 prevalent fragility fracture), to women aged ≥75 irrespective of
BMD, and to patients with T-score<−1.5+≥1clinical risk factor or
T-score<−1.0+≥2 clinical risk factors or FRAX-determined 10-year
hip fracture probability ≥3%
Zoledronate Denosumab s.c.,
or possibly oral BP
4 mg IV q6mo
60 mg s.c. q6mo
As long as AI
therapy(Rizzoli et al.) [50]
Abbreviations: AI, aromatase inhibitor; ASCO, American Society of Clinical Oncology; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; GnRH, gonadotropin-
releasing hormone; IV, intravenous; LS, lumbar spine; mo, month; NCCN, National Comprehensive Cancer Network; PO, oral; q, every; TH, total hip; UK, United Kingdom; wk, week; yr,
year.
a Limited evidence for the use of other agents was available when these guidelines were written.
b Calcium and vitamin D supplements are to be used in conjunction with BPs, and exercise when appropriate is recommended by most panels.
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nates in women with BC [72]. In light of these developments, we have
updated our recommendations for the prevention and treatment of AIBL
in postmenopausal women with early breast cancer [5].
2. Methods
2.1. Systematic literature review
With regard to clinical prognostic risk factors for fracture in breast
cancer patients, we used a recent systematic review [5]. For prevention
and treatment of AIBL, we undertook PubMed® searches of MEDLINE®
(National Library of Medicine, Bethesda, MD) and other databases were
performed to identify clinical trials of antiresorptive agents used for the
prevention and treatment of AIBL from Jul 2010 through April 2016. In
addition, the Cochrane Register of Controlled Trials and databases of
ongoing and unpublished trials http://www.clinicaltrials.gov were
searched. Additional information was obtained from abstracts pre-
sented at international meetings including the St. Gallen Breast Cancer
Conference, European Breast Cancer Conference (EBCC), San Antonio
Breast Cancer Symposium (SABCS), and ASCO annual meetings and
breast cancer symposia (Table 2).
An evidence-based medicine approach was used to determine when
to initiate antiresorptive therapy for AIBL, to determine the appropriate
antiresorptive therapy, and to deﬁne follow-up/monitoring procedures.
All reports were reviewed and the available data assessed for the level
of evidence used to guide treatment recommendations (Table 3).
3. Identiﬁcation of fracture risk in women with breast cancer
Several additional clinical risk factors have been validated in large,
prospective, population-based studies in postmenopausal women and
were previously characterized according to their impact on overall
fracture risk independently of both age and BMD (Evidence level IA)
[5]. Risk factors found to increase fracture risk in women with breast
cancer in addition to AI therapy included, T-score< –1.5, age>65
years, low BMI (< 20 kg/m2), family history of hip fracture, personal
history of fragility fracture after age 50, oral corticosteroid use> 6
months, rheumatoid arthritis, and smoking [73–79] (Evidence level IA).
Additionally, a recent study suggests that cancer associated muscle
weakness leads to increased immobility with an increased risk for
osteoporosis and fracture [80]. Recent data suggest that BMD measure-
ment alone should not be the sole criterion for determining fracture
risk, and that an overall fracture risk assessment that combines risk
factors provides a more accurate evaluation. It is also important to note
that the use of corticosteroids at a dose of> 2.5 mg prednisolone (or
equivalent) daily for more than 3 months is an established risk factor
based on data from non-malignant disease settings. When combined
with chemotherapy regimens, the doses of oral corticosteroids are
typically higher, and might negatively impact bone health over a
shorter period of time. Finally, in order to identify and manage
secondary causes of osteoporosis, complete baseline laboratory assess-
ments should include serum levels of calcium, phosphate, 25-OH
vitamin D, C-reactive protein, alkaline phosphatase, thyroid-stimulat-
ing hormone, and gamma-glutamyl transpeptidase; complete blood
count; creatinine clearance; and protein electrophoresis (serum and/
or urine).
4. Selecting a treatment to prevent AIBL
Available data from randomized clinical trials in more than 6000
patients suggest that denosumab, intravenous and oral bisphosphonates
can eﬀectively prevent AIBL in patients with breast cancer (Table 2)
Table 2
Major trials of antiresorptive agents for prevention of aibl in postmenopausal women with breast cancer.
Antiresorptive agent (Trial) N BMD data,
na
Dose Treatment duration Follow-up,
months
Mean BMD increase from baseline, %
LS TH
Zoledronate 1,065 1,065 4 mg q6mo 5 yr 36b 4.39 1.9
(ZO-FAST) [69]
Zoledronate 602 602 4 mg q6mo 5 yr 61 6.19 2.57
(Z-FAST) [81]
Zoledronate 558 395 4 mg q6mo 5 yr 24 4.94 1.22
(N03CC) [82]
Zoledronate 527 527 4 mg q6mo 5 yr 36 5.98 NR
(E-ZO-FAST) [83]
Denosumab 252 252 60 mg q6mo 2 yr 24 6.2c 3.7c
(HALT-BC) [84] 3420 3420 60 mg q 6mo 3 yr 36 10,2 7,92
Denosumab Fracture reduction:
(ABCSG-18) [92,93] OR 0.53 (CI 0.333–0.85,
p=0.009)
Risedronate 154 111 35 mg/wk 2 yr 24 2.2 1.8
(SABRE) [85]
Risedronate [86] 87 87 35 mg/wk 2 yr 24 0.4 0.9
Clodronate [87] 61 61 1,600 mg/day 3 yr 60 –1.0 –0.1
Risedronate (IBIS II- Stratum II) [88] 260 150 35 mg/wk 3 yr 36 1.1 -0.7
1410 903 35 mg/wk 3 yr 36 1,1% -0,7%
213 132 35 mg/wk 2 yr 24 5,7% 1,6%Risedronate
(IBIS II) [106]
Risedronate
(ARBI) [106]
Ibandronate 131 50 150 mg/mo 5 yr 60 5.01% 1.19%
(ARIBON) [89]
Risedronate [90] 118 11 35 mg/wk 1 yr 12 4.1 1.8
303 303 70 mg/wk 3 yr 36 15.6 (osteoporosic) 5.6 (osteoporotic)Alendronate
(BATMAN)[109]. 6.3 (osteopenic) 6.3 (osteopenic)
Abbreviations: AI, aromatase inhibitor; AIBL, aromatase inhibitor-associated bone loss; BMD, bone mineral density; LS, lumbar spine; mo, months; NR, not reported; TH, total hip; yr,
years.
a Number of patients randomized to bisphosphonate vs placebo and evaluable for BMD at the reported timepoint;
b BMD data available for 36 months’ follow-up; disease recurrence outcomes available for 48 months’ follow-up.
c Estimates based on published graph.
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[69,81–90]. Although the majority of these trials were not designed
with a fracture prevention endpoint, data from the osteoporosis setting
support the use of BMD improvements as a surrogate for fracture
prevention [91]. Therefore, data from these large RCTs may be
considered level II evidence for preserving skeletal health during AI
therapy.
4.1. Denosumab
4.1.1. Level of evidence: I
The Adjuvant Denosumab in Breast Cancer Trial (ABCSG-18) is the
only study to have fracture incidence as the primary endpoint and was
adequately powered to investigate the eﬀect on fracture risk [31]. The
trial compared adjuvant denosumab (60 mg s.c. twice yearly) with
placebo in 3425 postmenopausal women receiving adjuvant AI and
calcium and Vitamin D if warranted [92,93]. Postmenopausal women
with hormone receptor positive breast cancer treated with denosumab
had a signiﬁcant risk reduction of any clinical fracture (hazard ratio
[HR] 0.50 [95% CI 0.39–0·65], p< 0.0001). Denosumab treatment
furthermore signiﬁcantly decreased the number of incident morpho-
metric vertebral fractures and worsening of prevalent vertebral frac-
tures over 36 months (odds ratio 0.54 [95% CI 0.34–0·84], p=0.007).
The fracture risk reduction appeared to be irrespective of age and
baseline BMD. As a result, study patients were oﬀered optional
unblinding so that women in the placebo group could receive denosu-
mab.
The total number of adverse events did not diﬀer between the
groups. Speciﬁcally, the risk for osteonecrosis of the jaw (ONJ) was
monitored proactively and no case out of 31 suspected cases met the
diagnostic criteria. This result contrasts with reports from trials of
monthly denosumab 120 mg in the metastatic setting, which revealed
an ONJ risk of around 1% per year on treatment that is similar to the
ONJ risk during long term 3–4 weekly IV bisphosphonate therapy
[94–96]. Preventive dental care and the use of antibiotics during dental
procedures to minimize ONJ risk are recommended for all patients
initiating denosumab treatment. Further long-term safety data are
warranted to fully elucidate ONJ risks with six monthly denosumab
in the AIBL setting. After discontinuation of denosumab treatment, a
rebound eﬀect has been reported leading to an increase of markers of
bone turnover exceeding baseline levels as well an accelerated BMD
loss [97,98]. Recently, several case reports describe multiple vertebral
fractures after treatment cessation of denosumab. Therefore, a sequen-
tial treatment with an i.v. bisphosphonate after stopping denosumab
has been proposed [99,100].
4.2. IV bisphosphonates
4.2.1. Level of evidence: II
The data supporting IV bisphosphonate therapy to prevent AIBL in
postmenopausal women with early breast cancer comes predominantly
from 4 independent studies with a total of more than 2700 postmeno-
pausal women with early breast cancer (Table 2) [69,81–83]. The 3
companion Zometa®-Femara® Adjuvant Synergy Trials (Z-FAST, N
=602; ZO-FAST, N=1065; E-ZO-FAST, N=527) compare the eﬃcacy
of zoledronate (4 mg IV q6mo) given in conjunction with AI therapy
(immediate group), or after a BMD decrease to a T-score< –2.0 at any
side or a non-traumatic fracture (delayed group) [69,81,83]. The ﬁnal
61-month update from Z-FAST showed that delaying zoledronate
resulted in losses in BMD at lumbar spine (LS) and total hip (TH)
(–2.42% and –4.12%, respectively; P≤0.0003 for both vs. baseline)
[101]. However, patients who immediately initiated zoledronate con-
tinued to gain BMD at the lumbar spine (LS) and total hip (TH) (6.19%
and 2.57%, respectively; P≤0.0003 for both vs. baseline). Similar
results for the 60-month analyses of the ZO-FAST studies conﬁrmed that
immediate zoledronate not only prevented bone loss, but patients
continued to gain BMD during the 5 years of therapy (Table 2)
[69,83,102]. Women receiving immediate zoledronate gained BMD at
LS and TH (4.39% and 1.6%, respectively; P<0.0001 vs. delayed
group for both), versus BMD losses at both sites in the delayed
zoledronate group (–5.4% and –4.2%, respectively; P<0.0001 vs.
baseline for both). Similar BMD gains and losses were observed in E-ZO-
FAST at 36 months’ follow-up [83].
Another trial examined the eﬃcacy of zoledronate (4 mg IV q6mo)
for preventing AIBL in postmenopausal women with endocrine-respon-
sive breast cancer who started adjuvant letrozole after completing ≤6
years of tamoxifen treatment [82]. Similar to the BMD increases seen in
the Z-FAST, ZO-FAST, and E-ZO-FAST studies, women in the N03CC
(ALLIANCE) trial who received immediate zoledronate had signiﬁcantly
increased mean BMD at LS (3.66% at 12 months and 4.94% at 24
months) and TH (1.02% at 12 months and 1.22% at 24 months)
compared with baseline (P<0.001 for all comparisons) [82]. At the
12- and 24-month post-baseline assessments, women in the delayed
zoledronate group lost BMD at the LS (–1.66% and –2.28%, respec-
tively) and TH (–1.41% and –3.34%, respectively).
None of these studies (Z-FAST, ZO-FAST, and E-ZO-FAST and
NO3CC Study) were designed to show a signiﬁcant diﬀerence in
fracture incidence between the treatment arms [103]. Despite the
absence of fracture data, the BMD data from these 4 well-designed
RCTs demonstrates that zoledronate (4 mg q6mo) at initiation of AI
therapy can eﬀectively prevent AIBL in postmenopausal women.
Zoledronate given on a 6 monthly schedule appears to be very well
tolerated. The most common adverse events are transient infusion-site
reactions and mild ﬂu-like symptoms with rare renal adverse events and
exceptionally osteonecrosis of the jaw (ONJ). [69,81–83].
4.3. Oral bisphosphonates
4.3.1. Level of evidence: II-III
Several randomized clinical trials have investigated the eﬃcacy of
oral bisphosphonates for preventing AIBL (Table 2) [85–90,104,105].
Table 3
Summary of key clinical points and levels of evidence for adjuvant BP treatment
recommendations.
Source:Adapted by Hadji et al. [72].
Summary of key clinical points and levels of evidence for adjuvant BP treatment
recommendations
Prevention of AIBL
Postmenopausal women at low risk of recurrence
– Chemotherapy unlkely to have a direct aﬀect on bone
– Tamoxifen reduces fracture risk
– Als induce bone loss
– Assessment of fracture risk with regard to clinical risk factors, +/–BMD in
accordance to position statement
– Ensure adequate calcium and vitamin D intake
– Consider Denosumab (I,A) or BPs (lll-IV, A) if T score ≤2.0 or ≥2 clinic risk
factors for fracture
(BPscan include zoledronic acid (4 mg IV Q6 months) (II,A), risedronate (35 mg PO
weekly) (lll,A), ibandronate (150 mg PO monthly) (IV, A) alendronate (70 mg PO
weekly), (IV, A)
Prevention of metastases and improving disease outcomes
Premenopausal women on adjuvant ovarian suppression
– BPs should be considered to prevent CTIBL and metastases (l,A)
– Recommended BP is zoledronic acid [4 mg IV Q6 months) or clodronate
(1600 mg PO daily) (l,A)
– BPs should be initiated at the start of adjuvant therapy (ll, A)
– Duration of BP treatment should not exceed duration of ovarian suppression
unless indicated for low T-score (3-5 years) (ll,A)
Postmenopausal women at intermediate or high risk of recurrence
– BPs should be considered to prevent metastases irrespective of fracture risk (1,A)
– Recommended BPs are zoledronic acid (4 mg IV Q6 months) or clodronate
(1600 mg PO daily) (1,A)
– EPs should be initiated at the start of adjuvant therapy (ll,A)
– Duration of BP treatment should be 3-5 years and only continued after 5 years if
indicated by fracture risk (ll,A)
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Because of the complex trial designs of some of these studies, the
numbers of patients randomized to AI therapy alone versus AI therapy
plus bisphosphonate is much smaller than the overall number of
patients enrolled. Therefore, the evidence for oral bisphosphonates is
less robust compared to IV zoledronate.
The Study of Anastrozole with the Bisphosphonate Risedronate
(SABRE) compared the eﬃcacy of risedronate (35 mg/wk oral) versus
placebo for 2 years in postmenopausal women with hormone receptor-
positive early breast cancer receiving adjuvant anastrozole who also
had a moderate risk of fragility fracture (n=154) [85]. At 24 months,
oral risedronate signiﬁcantly increased LS BMD by 2.2% and TH BMD
by 1.8% versus baseline (P<0.0001 for each vs. placebo). A similar
trial in postmenopausal women with breast cancer receiving AI therapy
demonstrated that oral risedronate (35 mg/wk) initially improved BMD
versus baseline, but only modestly increased LS BMD (0.4%) and TH
BMD (0.9%) at 24 months [86]. Among women enrolled in the
International Breast Cancer Intervention Study (IBIS-II) bone substudy
(n=613), women with osteopenia (n =59) receiving anastrozole plus
risedronate (35 mg/wk) had better LS (0.32%) and TH (0.67%) BMD
compared with women receiving anastrozole alone after 36 months of
follow up [88]. The 3-year results showed that risedronate could
prevent bone loss over the three years at the spine although the
treatment was less eﬀective at the hip [106]. These observations are
consistent with the outcome of the Arimidex Bone Mass Index Oral
Bisphosphonate (ARBI) trial in which 35 mg oral risedronate weekly
was added to anastrozole in osteopenic patients which led to a
signiﬁcant increase of lumbar spine BMD over 2 yrs of 6.6% (n=93)
[106]. The most recent RCT including risedronate vs. placebo was
reported by Greenspan in which, after 24 months of follow up, BMD
increased more in the active treatment group compared to placebo with
an adjusted diﬀerence at 24 months of 3.9% at the spine and 3.2% at
the hip (both p< 0.05). Additionally, the adjusted diﬀerences in bone
turnover markers between the active treatment and placebo groups
were 0.09±0.04 nmol/LBCE for CTX and 23.3±4.8 μg/mL for P1NP
(both p<0.05). Women with greater 12-month decreases in CTX and
P1NP in the active treatment group had a greater 24-month increase in
spinal BMD (p<0.05) [107].
In the 60-month analysis of the Arimidex®-Bondronat® (ARIBON)
study, monthly oral ibandronate (150 mg) prevented bone loss in
osteopenic women (n=25) compared with placebo (n=25) and in a
small number of patients with pre-existing osteoporosis (n=13) Oral
ibandronate increased LS BMD by 5.01% and TH BMD by 1.19%
[89,108].
In the BATMAN study, all 303 postmenopausal women with early
breast cancer (EBC) received anastrozole (1 mg daily), calcium and
vitamin D weekly [109]. All osteoporotic patients received weekly
alendronate (70 mg) while osteopenic patients received alendronate or
placebo in accordance to a given algorithm. At three years, lumbar
spine mean BMD increased (15.6%, p<0.01) in the osteoporotic
group. BMD in the osteopenic group with early intervention increased
at three years (6.3%, p=0.02). No signiﬁcant change was seen in the
late intervention group. No change was observed in those with
osteopenia without alendronate. There was a signiﬁcant drop in lumbar
spine (−5.4%) and hip (−4.5%) mean BMD, in the normal BMD group,
none of whom received alendronate [110] A second short term RCT
randomly assigned patients to 5 mg of alendronate and 0.5 μg of
calcitriol or placebo. After 24-week of treatment, between group
diﬀerences is lumbar spine BMD was 3.0% (p<0.005). The increase
in C-telopeptide after 24 weeks was signiﬁcantly less in the treatment
group compared with that in the placebo group (35.2±17.5% vs.
109.8±28.6%, p<0.05) [109]. In all of the studies of oral bispho-
sphonates, patients who did not receive a bisphosphonate experienced
substantial BMD loss during AI therapy [111].
Oral bisphosphonates were generally well tolerated in these trials.
However, the rigid dosing requirements for oral bisphosphonates
(fasting before and after dosing, the need to remain upright after
dosing, etc) have been associated with some inconvenience for patients
(Table 4). Moreover, patients’ compliance and persistence with oral
therapies is suboptimal, even with potentially life-saving interventions
such as adjuvant endocrine therapy [112,113]. In the case of supportive
treatments such as antiresorptives, insights from the osteoporosis
setting show very low long-term adherence to treatment [114]. In
one study, less than 20% of patients receiving daily bisphosphonate
achieved clinically relevant persistence levels over 1 year, compared
with approximately 30% of patients receiving weekly bisphosphonate
[115]. In this setting, non-persistence has been associated with
increased fracture rates (ie, poor clinical outcomes) [116,117]. Trends
toward better compliance with less-frequent dose schedules have been
reported in multiple studies in women with postmenopausal osteoporo-
sis [118–120]. Because of the strong association between compliance
and clinical outcome [119], strategies to improve patients’ compliance
and persistence with oral bisphosphonate therapy are necessary to
ensure beneﬁt from these agents in the AIBL setting.
Table 4
Comparison of antiresorptive agents.
Agent Advantages Limitations Long-term safety
Oral bisphosphonates • Oral (self) administration • Limited eﬃcacy data available• Need to follow strict dosing guidelines• Poor compliance and persistence• No data for risedronate or alendronate to
assess eﬀects on underlying breast cancer
• Established in the osteoporosis setting• Generally well tolerated
IV bisphosphonates
(Zoledronate)
• Eﬃcacy data from large trials with long follow-
up
• Can be administered during routine twice-
yearly oncologist visits
• Compliance can be ensured
• IV administration by healthcare provider • Established in the osteoporosis and
AIBL settings
• Generally well tolerated• Adverse events are generally mild and
manageable
Denosumab • Can be administered during routine twice-
yearly oncologist visits or administration by
healthcare provider
• Compliance can be ensured
• Limited eﬃcacy data available• Rebound eﬀect after treatment
termination
• Costs
• Established in the osteoporosis and
AIBL settings with anti-fracture
eﬃcacy in both
• Generally well tolerated• Adverse events are generally mild and
manageable
Abbreviations: AIBL, aromatase inhibitor-associated bone loss; IV, intravenous; sc, subcutaneous.
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5. Treatment and follow-up recommendations for patients
receiving aromatase inhibitors
5.1. Fracture prevention
5.1.1. Level of evidence: I
5.1.1.1. Grade of recommendation: A. Our guidance for antiresorptive
therapy to treat or prevent AIBL in women with early breast cancer is
derived from well-designed randomized controlled studies, and is based
on validated risk factors with or without BMD measurements (Evidence
level 1A) (Fig. 1). All patients beginning AI therapy should be advised
to exercise moderately (resistance and weight-bearing exercise).
Whereas weight-bearing exercise has beneﬁcial eﬀects on BMD [121]
(Evidence level 1A), fracture risk reduction has not been demonstrated
[122,123] (Evidence level 1A). With regard to calcium and vitamin D,
the International Osteoporosis Foundation recommends a daily intake
of 1200 mg calcium and 800–1000 IU vitamin D for postmenopausal
women (guidelines available at www.iofbonehealth.org). Elderly
women, or those with reduced physical activity and sunlight
exposure, may need higher levels of these nutrients. For these high-
risk for fracture individuals, the measurement of 25-OH Vitamin D
levels is recommended and high dose vitamin D supplementation given
if deﬁcient [124]. For other postmenopausal women receiving AI
therapy, a dose of at least 800 (and up to 2000) IU of vitamin D
every day is recommended to maintain replete levels. It is important to
note, that a recent meta-analysis has underlined that the use of Vitamin
D+/-calcium supplementation alone has been shown to be ineﬀective
for fracture risk prevention in women with breast cancer (Evidence
level 1 A) [125].
For patients initiating an AI treatment not receiving bisphosphonate
for recurrence prevention, a BMD measurement is advised. Patients
with a T-score>−2.0 and no other fracture risk factor, BMD and risk
status should be reassessed after 12 months. If no adjuvant antiresorp-
tive therapy is initiated an annual BMD decrease of ≥5–10% should
trigger investigation for secondary causes of bone loss such as vitamin D
deﬁciency etc. and an antiresorptive treatment for fracture prevention
initiated. All patients initiating or receiving AI therapy with any 2 of the
following risk factors should receive antiresorptive therapy: T-score<
–1.5, age> 65 years, low BMI (< 20 kg/m2), family history of hip
fracture, personal history of fragility fracture after age 50, oral
corticosteroid use of> 6 months, and current or history of smoking.
Any patient initiating or receiving AI therapy with a T-score< –2.0
should receive antiresorptive therapy irrespective of the presence of
other risk factors. Based on current evidence, subcutaneous denosumab
(60 mg twice yearly) and intravenous zoledronate (4 mg q6mo) are the
preferred agents for prevention and treatment of AIBL. The advantages
and limitations of the diﬀerent antiresorptive therapies investigated in
the AIBL setting are summarized in Table 4.
For oral bisphosphonates, 35 mg risedronate/week is the bispho-
sphonate with the strongest evidence for prevention of AIBL. In all
patients receiving oral bisphosphonate therapy, BMD should be mon-
itored and compliance assessed every 1–2 years. Periodic assessment of
bone resorption markers may oﬀer a convenient, noninvasive measure
of compliance with therapy [5,126]. In case of poor compliance or
unsatisfactory BMD changes after 1–2 years, a switch to denosumab or
intravenous bisphosphonate is recommended. For patients receiving
denosumab, intravenous bisphosphonates or other agents, BMD mon-
itoring during therapy should be performed on an individualized basis
and in accordance to local guidelines.
Patients receiving AIs are at elevated risk for fracture for at least the
duration of AI treatment [26]. As a result, we recommend continuing
antiresorptive therapy for as long as the patient is receiving an AI (up to
5–10 years). Currently, denosumab and zoledronate are the only
antiresorptive agent with proven eﬃcacy and safety in large prospec-
tive RCTs over a long duration [81,101]. Consequently, side-eﬀect
proﬁles and management should be taken into account when selecting
an antiresorptive agent to prevent or treat AIBL.
5.2. Disease recurrence prevention – adjuvant bisphosphonate
5.2.1. Level of evidence: I
5.2.1.1. Grade of recommendation: A. Important evidence was provided
by the recent Early Breast Cancer Trialists Collaborative Group
(EBCTCG) meta-analysis of data of> 18,000 patients from
postmenopausal breast cancer patients showing that adjuvant
bisphosphonates (i.v. zoledronate, oral clodronate and oral
ibandronate) reduce recurrences in bone and prolong survival in
postmenopausal women [71]. Overall, despite a reduction in bone
metastases, BPs had no signiﬁcant eﬀect on breast cancer recurrence
(rate ratio 0.94) and the eﬀect on breast cancer mortality, though
signiﬁcant, was small (RR=0.91). However, in postmenopausal women
or those receiving ovarian surpression with goserelin, clinically
Fig. 1. Recommended algorithm for managing bone health in women receiving aromatase inhibitor (AI) therapy for breast cancer.
*If patients experience an annual decrease in bone mineral density (BMD) of≥10% (using the same DXA absorptiometry machine), secondary causes of bone loss such as vitamin D deﬁciency
should be evaluated and antiresorptive therapy initiated. Use lowest T-score from 3 sites. Abbreviations: AI, aromatase inhibitor; BMD, bone mineral density; BMI, body mass index.
Adapted from Hadji et al. [5].
P. Hadji et al. Journal of Bone Oncology 7 (2017) 1–12
7
important beneﬁts were seen with improvements in overall breast
cancer recurrence (RR=0.86), distant recurrence at any site
(RR=0.82), bone recurrence (RR=0.72) and breast cancer-speciﬁc
mortality (RR=0.82) (Fig. 2) (Evidence level 1A) [71]. In spite of the
outstanding evidence and its magnitude it must be noted that
bisphosphonates do not currently have regulatory approval for the
prevention of breast cancer recurrence which currently limits the
ability to prescribe these agents unless the patient fulﬁlls the AIBL
criteria for intervention.
Recently, an international expert panel of oncologists and bone
experts has published a consensus statement recommending the routine
use of adjuvant bisphosphonates in women with BC at intermediate or
signiﬁcant risk for disease recurrence due to adverse clinical or
biological characteristics such as node positive disease, a T2 or above,
grade II/III breast tumor or disease found to be ER negative or HER-2
positive (Fig. 3) [72]. This include where available, that women with
breast cancer may be recommended to receive bisphosphonates irre-
spective of fracture risk. In this setting, BMD monitoring may not be
necessary.
5.3. Disease recurrence prevention – denosumab
5.3.1. Level of evidence: III
5.3.1.1. Grade of recommendation: C. Early disease free survival (DFS)
results from the ABCSG-18 study suggest a beneﬁt on disease recurrence
with an absolute decrease in events of 2.1% at ﬁve years compared to
placebo. Hereby, disease free survival was signiﬁcantly reduced in
patients on denosumab vs. placebo HR 0.87 (CI 0.66–0.99; p< 0.041)
in the sensitivity analysis but not in the ITT (HR 0.816, CI 0.66–1.00;
p<0.051) analysis [72]. The follow-up was too short to see eﬀects on
mortality. Further reports as of the D-CARE study results are anticipated
in the next 12–18 months and will help to deﬁne the role of denosumab
as a disease modifying agent.
Fig. 2. Eﬀects of adjuvant bisphosphonates on disease recurrence (A), bone recurrence (B) and breast cancer mortality (C) in postmenopausal women. Data from the EBCTCG meta-
analysis of randomized clinical trials [72].
Fig. 3. *If not clinically assessable i.e. hysterectomy/IUD then ensure serum FSH is in postmenopausal range. Ensure patient is not receiving concurrent therapies that can aﬀect the HPG
axis. δInclude vitamin D 1000-2000IU and calcium 1000 mg/day.
Selection of patients suitable for adjuvant bisphosphonates to prevent metastases Adapted by Hadji et al. [72].
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6. Conclusions and future directions
It is evident that, in addition to BMD, clinical risk factors can greatly
inﬂuence fracture risk. In addition to morbidity and mortality, fractures
are associated with high healthcare costs and increased healthcare
utilization for several months after fracture incidence [127–129]. In the
European Union the economic burden of incident and prior fragility
fractures was estimated at € 37 billion in 2010. Acute hip fracture costs
in Europe were € 13,800 but varied widely from approximately €2000
in Bulgaria to about €25,000 in Denmark [130]. Additionally, vertebral
and especially hip fractures are likely to result in prolonged disability
and loss of independence, thereby leading to increased indirect costs.
Improvements in assessing fracture risk can help identify patients who
need pharmacologic intervention to improve bone health, thereby
reducing fracture incidence. We have presented an evidence-based
algorithm for assessing bone health in women with breast cancer and
initiating antiresorptive therapy in postmenopausal women initiating
AI therapy for early stage breast cancer as well as in other postmeno-
pausal women not being considered for an AI treatment and in those
receiving ovarian suppression therapies. Based on current evidence, six
monthly denosumab or zoledronate for the duration of AI therapy is
recommended for the prevention of AIBL in postmenopausal women
receiving adjuvant AI therapy with zoledronate recommended when
eﬀects on disease recurrence are the priority and denosumab when
fracture risk is the dominant concern. Long-term eﬃcacy and safety
data for other agents continue to mature, and should be taken into
consideration as they become available.
In addition to the established risk factors used in our bone health
algorithm, other potential fracture risk factors in women with breast
cancer include chemotherapy, radiotherapy, low weight, and family
history of hip fractures. Further studies examining the role of these
factors are warranted. Furthermore, periodic (annual) assessment of
breast cancer patients with these potential risk factors may be prudent.
Overall, data from the AIBL setting as well as long-term use in the
treatment of postmenopausal osteoporosis indicate that denosumab and
bisphosphonates are safe and eﬀective agents for preserving bone
health during adjuvant endocrine therapy for breast cancer. In addition,
emerging anticancer beneﬁts from bisphosphonates provide additional
reasons to proactively use these agents during adjuvant AI treatment.
Ongoing trials and the recent Oxford-meta analysis underlined the
potential of oral and intravenous bisphosphonates and perhaps of
denosumab to prevent breast cancer bone recurrence and to increase
breast cancer survival. Therefore, the role of antiresorptive agents in
early breast cancer has signiﬁcantly been extended.
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